# ALX Oncology Announces That CD47 Biomarker Data from Clinical Trial Evaluating Evorpacept + Zanidatamab Combination in Advanced Breast Cancer Will Be Presented at ESMO Breast Cancer 2026
Canonical URL: https://biopharmsignal.com/news/ALXO/alx-oncology-announces-that-cd47-biomarker-data-from-clinical-trial-evaluating-evorpacept-zanidatamab-combination-in-advanced-breast-cancer-will-be-presented-at-esmo-breast-cancer-2026
Ticker: ALXO
Company: ALX Oncology
Source: ALX Oncology
Published: 2026-04-30 12:01 EST
Original Source URL: https://ir.alxoncology.com
## Summary

- Company Will Discuss Data and Report First Quarter 2026 Financial Results on May 8 - SOUTH SAN FRANCISCO, Calif., April 30, 2026 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc. ("ALX Oncology"; Nasdaq: ALXO), a clinical-stage biotechnology company advancing a pipeline of novel therapies designed

## Article Body
- Company Will Discuss Data and Report First Quarter 2026 Financial Results on May 8 - SOUTH SAN FRANCISCO, Calif., April 30, 2026 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc. ("ALX Oncology"; Nasdaq: ALXO), a clinical-stage biotechnology company advancing a pipeline of novel therapies designed
## Recent Company News
- 2026-06-01 12:00 EST — [ALX Oncology to Present at the 2026 Jefferies Global Healthcare Conference in New York](https://biopharmsignal.com/news/ALXO/alx-oncology-to-present-at-the-2026-jefferies-global-healthcare-conference-in-new-york) — Source: ALX Oncology
- 2026-05-08 12:00 EST — [ALX Oncology Reports First Quarter 2026 Financial Results and Provides Corporate Update](https://biopharmsignal.com/news/ALXO/alx-oncology-reports-first-quarter-2026-financial-results-and-provides-corporate-update) — Source: ALX Oncology
- 2026-05-07 12:00 EST — [ALX Oncology’s Evorpacept in Combination with Zanidatamab Generates Promising, Durable Response in Patients with Advanced HER2-Positive Breast Cancer and High CD47 Expression](https://biopharmsignal.com/news/ALXO/alx-oncology-s-evorpacept-in-combination-with-zanidatamab-generates-promising-durable-response-in-patients-with-advanced-her2-positive-breast-cancer-and-high-cd47-expression) — Source: ALX Oncology
- 2026-04-30 12:01 EST — [ALX Oncology Announces That CD47 Biomarker Data from Clinical Trial Evaluating Evorpacept + Zanidatamab Combination in Advanced Breast Cancer Will Be Presented at ESMO Breast Cancer 2026](https://biopharmsignal.com/news/ALXO/alx-oncology-announces-that-cd47-biomarker-data-from-clinical-trial-evaluating-evorpacept-zanidatamab-combination-in-advanced-breast-cancer-will-be-presented-at-esmo-breast-cancer-2026) — Source: ALX Oncology
- 2026-04-17 20:05 EST — [ALX Oncology Reports Inducement Grant as permitted by the Nasdaq Listing Rules](https://biopharmsignal.com/news/ALXO/alx-oncology-reports-inducement-grant-as-permitted-by-the-nasdaq-listing-rules) — Source: ALX Oncology
## Related News
- 2026-07-22 20:05 EST — AZTA — [Azenta Announces Fiscal 2026 Third Quarter Conference Call and Webcast](https://biopharmsignal.com/news/AZTA/azenta-announces-fiscal-2026-third-quarter-conference-call-and-webcast-48419fff)
- 2026-07-22 20:05 EST — VKTX — [Viking Therapeutics to Report Financial Results for Second Quarter 2026 on July 29, 2026](https://biopharmsignal.com/news/VKTX/viking-therapeutics-to-report-financial-results-for-second-quarter-2026-on-july--bbf2553f)
- 2026-07-22 20:01 EST — AXON — [Axon to Release Second Quarter 2026 Earnings on August 5, 2026](https://biopharmsignal.com/news/AXON/axon-to-release-second-quarter-2026-earnings-on-august-5-2026-66120902)
- 2026-07-22 12:39 EST — ARTL — [New Analysis of Over 50 Studies Showed that All the Non-Prescription CBD Products Researched Fell Short of Therapeutic Efficacy — Reinforcing the Case for Artelo's Optimized ART12.11 CBD Composition](https://biopharmsignal.com/news/ARTL/new-analysis-of-over-50-studies-showed-that-all-the-non-prescription-cbd-product-a3445432)
- 2026-07-22 12:30 EST — NRSN — [NeuroSense Advances PrimeC Toward New Drug Submission to Health Canada for ALS](https://biopharmsignal.com/news/NRSN/neurosense-advances-primec-toward-new-drug-submission-to-health-canada-for-als-721c198c)